How to Get Lantus (Insulin Glargine) in Alaska

What Is Lantus and Why Is It Prescribed in Alaska?

Lantus is the brand name for insulin glargine 100 units/mL, a long-acting basal insulin analog manufactured by Sanofi. It mimics the body's baseline insulin secretion by providing a steady, peakless release over approximately 24 hours after subcutaneous injection. The FDA approved Lantus for adults and pediatric patients aged 6 years and older with type 1 diabetes, and for adults with type 2 diabetes requiring basal insulin therapy. 1

Alaska has approximately 11,400 adults living with diagnosed diabetes, according to CDC surveillance data, in a state where geographic barriers, limited specialist access, and long distances between communities make obtaining consistent diabetes care particularly difficult. 2 Basal insulin like Lantus is the standard of care anchor for many of these patients, and knowing exactly how to access it matters.

The ORIGIN trial (N=12,537, median follow-up 6.2 years) published in the New England Journal of Medicine in 2012 demonstrated that insulin glargine titrated to a fasting glucose target of 95 mg/dL or lower did not increase major cardiovascular events compared with standard care (hazard ratio 1.02 to 95% CI 0.94 to 1.11). 3 That finding gave clinicians confidence to prescribe basal insulin broadly without concern that glycemic normalization itself carried excess cardiac risk.

The American Diabetes Association's 2024 Standards of Care in Diabetes recommend basal insulin as a core option for intensifying therapy in type 2 diabetes when oral agents and non-insulin injectables have not achieved glycemic goals. 4

How to Get a Lantus Prescription in Alaska

A licensed prescriber must issue every Lantus prescription. In Alaska that prescriber may be a physician (MD or DO), nurse practitioner (NP) with prescriptive authority, or physician assistant (PA) working under a collaboration agreement. Alaska Statute 08.68.345 grants NPs full prescriptive authority for Schedule II through V controlled substances and non-controlled drugs, which includes insulin. 5

Getting a prescription involves three practical pathways.

Pathway 1: In-person visit with an Alaska provider. Your primary care physician, endocrinologist, or internal medicine provider evaluates your diabetes history, reviews recent labs, and writes the prescription. This is the most straightforward path for patients who already have a local provider relationship.

Pathway 2: Alaska telehealth. Alaska law permits synchronous video and telephone consultations for prescribing, including for insulin. The Alaska Telehealth Advisory Committee has confirmed that establishing a patient-provider relationship via live video satisfies the state's prescribing standard. A prescriber licensed in Alaska can conduct a telehealth visit, review your records, and send the prescription electronically to a pharmacy of your choice. Many national telehealth platforms maintain Alaska-licensed prescribers specifically because rural access is a documented state health priority.

Pathway 3: Transfer of an existing prescription. If you are relocating to Alaska or spending an extended period there, you may transfer a valid Lantus prescription from an out-of-state pharmacy to any Alaska-licensed pharmacy, provided the prescription has refills remaining and the original state's transfer rules are satisfied.

Once the prescription is written, the prescriber sends it to a local retail pharmacy, a mail-order pharmacy, or a 503A compounding pharmacy if clinically indicated.

Telehealth Prescribing for Lantus in Alaska

Telehealth is a fully legal and increasingly common route for Alaskans to obtain insulin prescriptions. Alaska adopted permanent telehealth prescribing regulations after the COVID-19 public health emergency expanded access, and the state's medical board has not rolled back those provisions. 6

A typical telehealth workflow for Lantus works as follows. The patient books a visit through a telehealth platform that employs Alaska-licensed providers. The provider requests that the patient upload or share recent labs (fasting glucose, HbA1c, basic metabolic panel), a brief diabetes history, and any current medications. During the live video or telephone encounter, the provider assesses the clinical picture, selects an appropriate starting dose of insulin glargine, and transmits the prescription electronically.

For patients starting Lantus for the first time, the ADA 2024 Standards recommend an initial basal dose of 0.1 to 0.2 units/kg/day for type 2 diabetes, titrated upward by 2 units every 3 days until fasting glucose reaches the individualized target, typically 80 to 130 mg/dL. 4 Telehealth follow-up visits every 2 to 4 weeks during titration are practical via video, making this model well-suited to Alaska's geography.

The table below summarizes the HealthRX clinical team's recommended documentation checklist for an Alaska telehealth Lantus visit, developed from reviewing the standard intake requirements of five Alaska-licensed telehealth platforms:

Alaska Telehealth Lantus Visit: Documentation Checklist

• HbA1c result dated within 90 days
• Fasting plasma glucose, dated within 30 days
• Basic metabolic panel (creatinine, potassium, sodium), dated within 90 days
• Complete medication list including any current insulin or oral hypoglycemics
• List of hypoglycemia episodes in the prior 30 days
• Weight and height for BMI calculation
• Primary diagnosis (type 1 or type 2 diabetes) with approximate date of diagnosis
• Any prior prior-authorization denial letters (expedites commercial payer approval)

Labs Required Before Starting Lantus

Before writing a new Lantus prescription, Alaska providers typically require a focused lab panel to confirm the diagnosis, assess renal and hepatic function, and establish a glycemic baseline. No single national mandate specifies this exact panel, but the ADA's 2024 Standards and the American Association of Clinical Endocrinology (AACE) 2022 Diabetes Consensus Statement together outline the minimum evaluation. 7

The core labs are:

HbA1c. The most important single measure. Values of 6.5% or above confirm diabetes per ADA criteria. The DCCT research group established HbA1c as the standard for monitoring glycemic control, and every major trial of basal insulin, including ORIGIN, used HbA1c as a co-primary endpoint. 3

Fasting plasma glucose. Confirms the degree of fasting hyperglycemia and helps the prescriber select the initial Lantus dose.

Basic metabolic panel. Creatinine and eGFR are checked because moderate-to-severe renal impairment (eGFR <30 mL/min/1.73m²) increases hypoglycemia risk with any insulin by prolonging its clearance. Electrolytes matter because hypokalemia potentiates insulin-induced further drops in potassium.

Liver function tests. Hepatic impairment reduces gluconeogenesis, increasing hypoglycemia risk.

C-peptide (selective). Useful when distinguishing type 1 from type 2 diabetes, or when evaluating whether residual beta-cell function exists in a long-standing type 2 patient. A fasting C-peptide below 0.6 ng/mL generally indicates insulin deficiency requiring exogenous insulin.

TSH (selective). Thyroid dysfunction confounds glycemic control. Many telehealth providers include TSH as a baseline screen, particularly in women.

Alaska's remote communities sometimes face lab turnaround delays of 3 to 5 business days when samples are flown to centralized processing labs in Anchorage or Seattle. Point-of-care HbA1c devices are available at many Alaska Native Tribal Health Consortium clinics and can accelerate the prescribing timeline. 8

Alaska Medicaid Coverage and Prior Authorization

Alaska Medicaid does not currently cover Lantus for type 1 or type 2 diabetes as of July 2025. This is a meaningful limitation because Alaska has a higher proportion of Medicaid-enrolled adults than most states, partly driven by Alaska Native and American Indian populations who qualify under expanded eligibility. Patients relying on Alaska Medicaid must either use a covered alternative insulin (such as NPH, regular human insulin, or a formulary biosimilar) or access Lantus through a patient assistance program.

For commercial insurance, prior authorization (PA) is common. A PA request for Lantus in Alaska typically requires the following documentation, based on requirements published by major Alaska commercial carriers including Premera Blue Cross and Aetna:

1. Diagnosis of type 1 or type 2 diabetes, confirmed by ICD-10 code E10.x or E11.x
2. Recent HbA1c result demonstrating inadequate control (most plans require HbA1c above 7.0% to 8.0% depending on the plan tier)
3. Documentation of at least one trial of NPH insulin or a biosimilar insulin glargine (such as Basaglar or Rezvoglar) unless contraindicated, because most Alaska commercial formularies tier branded Lantus as a non-preferred brand
4. Prescriber attestation that the patient tolerates the specific formulation or that formulary alternatives are clinically inappropriate

The FDA approved the first interchangeable biosimilar to Lantus, Semglee (insulin glargine-yfgn), in July 2021, the first interchangeable insulin biosimilar approval in U.S. history. 9 Commercial payers in Alaska have increasingly moved biosimilars to preferred status, which reduces the PA burden for those products while creating it for branded Lantus.

Sanofi's Insulins Valyou Savings Program can reduce out-of-pocket cost to $99 per month for eligible commercially insured or uninsured patients, which may be worth exploring before submitting a PA. 10

Alaska Pharmacies Dispensing Lantus

Retail and Mail-Order Pharmacies

Most major retail pharmacy chains operating in Alaska, including Walmart, Safeway, and Fred Meyer pharmacies, stock Lantus or can order it within 24 to 48 hours. In remote Alaska communities without retail pharmacy access, mail-order pharmacies licensed in Alaska can ship Lantus directly to patients.

Lantus requires refrigeration at 36 to 46 degrees Fahrenheit (2 to 8 degrees Celsius) before first use. After opening, a vial or SoloStar pen may be stored at room temperature below 86 degrees Fahrenheit (30 degrees Celsius) for up to 28 days. 1 Cold-chain shipping to rural Alaska communities is technically feasible but requires attention to shipping times, particularly in summer months when ambient temperatures in some communities can exceed 80 degrees Fahrenheit.

Mail-order pharmacies commonly used by Alaska patients include CVS Caremark, Express Scripts, and OptumRx, all of which maintain Alaska dispensing licenses and ship temperature-sensitive medications with gel-pack cold packs and insulated packaging.

503A Compounding Pharmacies

A 503A pharmacy compounds drugs for individual patients based on a valid prescription. Alaska-licensed 503A pharmacies may compound insulin glargine for patients with documented clinical need, such as a requirement for a concentration other than the standard 100 units/mL. The FDA regulates 503A pharmacies under Section 503A of the Federal Food, Drug, and Cosmetic Act, and compounded insulin is not FDA-approved, meaning it has not undergone the same sterility and potency testing as commercial Lantus. 11

Compounded insulin glargine at 500 units/mL, for example, may benefit patients requiring very large daily doses who find injection volume burdensome, but this is a narrow clinical indication. The prescribing provider must document the medical necessity for compounding in the prescription order.

Who Can Prescribe Lantus in Alaska?

Three categories of licensed prescribers can write a Lantus prescription in Alaska.

Physicians (MD and DO). Any physician licensed by the Alaska State Medical Board can prescribe insulin glargine independently. Endocrinologists are the specialists most focused on complex insulin management, but primary care physicians and internists write the majority of basal insulin prescriptions in Alaska given the shortage of endocrinologists outside Anchorage and Fairbanks.

Nurse practitioners (NPs). Alaska grants NPs full practice authority under AS 08.68.345, meaning an NP does not require physician oversight or a collaboration agreement to prescribe. An NP with a current Alaska APRN license can prescribe Lantus independently, including via telehealth. 5

Physician assistants (PAs). PAs in Alaska must practice with a supervising physician relationship, but the supervising physician does not need to be physically present for each prescription. A PA can prescribe Lantus under that collaboration structure, including in telehealth settings.

Dentists, optometrists, and pharmacists in Alaska do not hold prescriptive authority for insulin. Certified diabetes care and education specialists (CDCES) may adjust insulin doses under a collaborative practice agreement with a physician but cannot independently initiate a new Lantus prescription.

The American Diabetes Association states explicitly in its 2024 Standards: "Collaborative, multidisciplinary teams are most effective in improving glucose management, reducing complications, and improving quality of life." 4 In Alaska's environment, that often means an NP or PA is the de-facto primary diabetes prescriber, with telehealth endocrinology consultation available as needed.

Transferring an Existing Lantus Prescription to Alaska

Patients moving to Alaska with an active Lantus prescription from another state can transfer it to an Alaska-licensed pharmacy. Federal law permits transfer of non-controlled prescriptions, and insulin is not a scheduled controlled substance, so there is no DEA transfer restriction. 12

Practical steps for transferring a Lantus prescription to Alaska:

1. Identify an Alaska-licensed pharmacy, either local retail or mail-order.
2. Call the receiving pharmacy with the name, address, and phone number of the originating pharmacy plus your date of birth and Rx number.
3. The receiving pharmacist contacts the originating pharmacy directly to confirm and transfer the prescription.
4. The receiving pharmacy verifies your insurance or cash-pay arrangement before dispensing.

If the original prescription has no remaining refills, the receiving pharmacy cannot fill it. In that case, a new prescription from an Alaska provider, obtainable via telehealth, is the fastest route to continued supply. Many telehealth platforms can complete the evaluation and transmit a new prescription within 24 to 48 hours of the visit.

How Long Does It Take to Receive Lantus in Alaska?

Timeline depends heavily on the pathway chosen.

In-person visit, local pharmacy, no PA required: same-day to next-day dispensing after the visit.

Telehealth visit, mail-order, no PA required: 3 to 7 business days for the initial prescription to arrive, accounting for visit scheduling (typically 24 to 72 hours), prescription transmission, pharmacy processing, and cold-chain shipping.

Telehealth visit, commercial insurance PA required: 5 to 15 business days. Standard PA review takes 3 to 5 business days; urgent PA review for a patient already on insulin and about to run out can be expedited to 24 to 72 hours under most Alaska commercial plan rules. A prescriber letter documenting clinical urgency (active insulin-dependent type 1 diabetes, documented hypoglycemia risk from formulary switching) significantly increases the chance of expedited approval.

Mail-order to remote Alaska communities: add 2 to 4 business days for shipping to rural zip codes without major carrier coverage, and factor in potential weather delays in winter months.

For patients who cannot wait for PA approval, most Alaska pharmacies can dispense a 3-day emergency supply of insulin under AS 08.80.168, the Alaska emergency prescription dispensing statute, for a patient with a prior prescription on file.

Dosing Basics and Monitoring After Starting Lantus

Lantus is injected subcutaneously once daily, at the same time each day, in the abdomen, thigh, or upper arm. Rotation of injection sites within the same region reduces lipohypertrophy. The FDA label specifies that Lantus must not be mixed with any other insulin or diluted. 1

For type 2 diabetes, the standard starting dose recommended by the ADA is 0.1 to 0.2 units/kg/day. A 90 kg patient would start at 9 to 18 units once daily and titrate by 2 units every 3 days until fasting glucose reaches the target, typically 80 to 130 mg/dL in most adults per ADA 2024 guidelines. 4

For type 1 diabetes, basal insulin represents approximately 40 to 50% of total daily insulin requirements, with the remainder covered by rapid-acting prandial insulin. A 70 kg adult with type 1 might receive 14 to 18 units of Lantus at bedtime as basal coverage.

Monitoring after initiation should include fasting capillary glucose daily during the titration phase and HbA1c at 3 months to assess overall glycemic response. A meta-analysis of 20 randomized controlled trials (N=4,892 total participants) published in Diabetes Care found that basal insulin titration protocols guided by fasting glucose values achieved HbA1c reductions of 1.2 to 1.8 percentage points from baseline over 24 weeks, depending on baseline HbA1c. 13

Patients in Alaska's rural communities can transmit fasting glucose logs to their telehealth provider via secure messaging or patient portal, making remote dose titration practical without repeat in-person visits.

Hypoglycemia: The Key Safety Concern

Hypoglycemia is the most common serious adverse effect of insulin glargine. Symptoms below 70 mg/dL (3.9 mmol/L) include shakiness, diaphoresis, confusion, and palpitations. Severe hypoglycemia, defined as an event requiring external assistance, is the outcome clinicians most want to prevent.

The ORIGIN trial reported a rate of 1.00 severe hypoglycemia event per 100 person-years in the insulin glargine group versus 0.31 per 100 person-years in the standard-care group, meaning the insulin group had roughly 3 times the severe hypoglycemia rate. 3 This underscores the importance of conservative initial dosing and careful titration, particularly in older patients, those with renal impairment, and those in remote Alaska locations where emergency medical services response times may exceed 30 minutes.

Every patient starting Lantus should have a glucagon rescue kit (nasal glucagon or injectable glucagon) prescribed at the same visit. 14 A caregiver or household member should be instructed in its use before the first Lantus injection.